Potential resistance of SARS-CoV-2 main protease (Mpro) against protease inhibitors: lessons learned from HIV-1 protease

JA Mótyán, M Mahdi, G Hoffka, J Tőzsér - International journal of …, 2022 - mdpi.com
Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome 2
(SARS-CoV-2), has been one of the most devastating pandemics of recent times. The lack of …

[HTML][HTML] Therapeutic potentials of CRISPR-Cas genome editing technology in human viral infections

S Najafi, SC Tan, S Aghamiri, P Raee… - Biomedicine & …, 2022 - Elsevier
Viral infections are a common cause of morbidity worldwide. The emergence of Coronavirus
Disease 2019 (COVID-19) has led to more attention to viral infections and finding novel …

[HTML][HTML] Utilization of immunological ratios in HIV: Implications for monitoring and therapeutic strategies

EI Obeagu, GU Obeagu - Medicine, 2024 - journals.lww.com
Human immunodeficiency virus (HIV) infection remains a significant global health concern,
necessitating ongoing research and innovation in the quest for improved disease …

Primary care guidance for persons with human immunodeficiency virus: 2020 update by the HIV Medicine Association of the Infectious Diseases Society of America

MA Thompson, MA Horberg, AL Agwu… - Clinical infectious …, 2021 - academic.oup.com
Advances in antiretroviral therapy (ART) have made it possible for persons with human
immunodeficiency virus (HIV) to live a near expected life span, without progressing to AIDS …

Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the International Antiviral Society–USA Panel

MS Saag, RT Gandhi, JF Hoy, RJ Landovitz… - Jama, 2020 - jamanetwork.com
Importance Data on the use of antiretroviral drugs, including new drugs and formulations, for
the treatment and prevention of HIV infection continue to guide optimal practices. Objective …

A Comparative Analysis of SARS-CoV-2 Antivirals Characterizes 3CLpro Inhibitor PF-00835231 as a Potential New Treatment for COVID-19

M de Vries, AS Mohamed, RA Prescott… - Journal of …, 2021 - Am Soc Microbiol
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiological agent of
coronavirus disease 2019 (COVID-19). There is a dire need for novel effective antivirals to …

[HTML][HTML] 2019 update of the drug resistance mutations in HIV-1

AM Wensing, V Calvez… - Topics in antiviral …, 2019 - ncbi.nlm.nih.gov
The 2019 edition of the IAS-USA drug resistance mutations list updates the Figure last
published in January 2017. The mutations listed are those that have been identified by …

[HTML][HTML] Highly active antiretroviral therapy (HAART)

JS Eggleton, S Nagalli - 2020 - europepmc.org
Objectives: Describe the treatment considerations for patients with HIV. Identify the most
common adverse events associated with highly active antiretroviral therapy (HAART) …

Transmitted drug resistance among human immunodeficiency virus (HIV)-1 diagnoses in the United States, 2014–2018

RP McClung, AM Oster, MCB Ocfemia… - Clinical Infectious …, 2022 - academic.oup.com
Background Transmitted human immunodeficiency virus (HIV) drug resistance can threaten
the efficacy of antiretroviral therapy and pre-exposure prophylaxis (PrEP). Drug-resistance …

Drug resistance mutations in HIV: new bioinformatics approaches and challenges

L Blassel, A Zhukova, CJ Villabona-Arenas… - Current opinion in …, 2021 - Elsevier
Highlights•Machine learning is increasingly used to predict and understand drug resistance
in HIV.•Phylogenetics helps to track the emergence and spread of HIV drug resistance …